Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.

This study revealed that WEE1 expression was increased after EGFR-TKIs resistance, and WEE1 knockdown could enhance chemosensitivity in EGFR-TKIs resistant NSCLC. It is suggested the combination of WEE1 inhibitor and chemotherapy might improve the clinical outcome of NSCLC patients with acquired EGFR-TKIs resistance. PMID: 31387179 [PubMed - in process]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research

Related Links:

Authors: Palussière J, Catena V, Lagarde P, Cousin S, Cabart M, Buy X, Chomy F Abstract Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death; percutaneous thermal ablation (TA) has proven feasibility, good local control and good tolerance in stage I tumors for patients with medical comorbidities and who are ineligible for surgery. In this context, stereotactic body radiotherapy (SBRT) has demonstrated high efficacy in treating T1 NSCLC and will need to be compared with percutaneous ablation. TA is also indicated in oligoprogressive disease; and can be proposed as a salvage treatment o...
Source: International Journal of Hyperthermia - Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research
ConclusionAtezolizumab regimens of 840  mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Locally advanced non-small cell lung cancer (LA-NSCLC) when radically treated with standard concurrent chemoradiotherapy has a high local recurrence rate of approximately 30% at 2  years [1,2]. Additionally, the overall survival rates are low, around 30% in selected patients at 5 years in recent clinical trials investigating modern chemoradiotherapy [3–5]. Treatment-induced toxicity may partly be responsible for these unfavorable results, as indicated by the higher mort ality in the high-dose arm of RTOG0617 [2,3].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
aacute;si Z, Reiniger L Abstract Survival of patients with lung cancer is unfavorable. Distant metastasis is detected in more than half of the patients at diagnosis. In advanced stages, platinum-based chemotherapy has been the main therapeutic approach for a long time, however, in 2004 targeted therapies emerged. Recently, PDL1/ PD-1 inhibitors have been introduced in the treatment of metastatic lung cancers, for which the therapeutic criteria are increasingly outlined. Based on international and Hungarian data, it is likely that determination of PD-L1 expression in the primary tumor samples may be sufficient for ...
Source: Magyar Onkologia - Category: Cancer & Oncology Authors: Tags: Magy Onkol Source Type: research
Abstract Long non-coding RNA taurine up-regulated gene 1 (TUG1) emerges as new players in gene regulation in several cancers; however, its mechanism of action in non-small cell lung cancer (NSCLC) has not been well-studied. Herein, we determined expression pattern of TUG1 in NSCLC and further identified its effect on the chemosensitivity of NSCLC. Low expression of TUG1 was found in NSCLC tissues obtained from non-responders to platinum-based chemotherapy and reflected poor overall survival. TUG1 overexpression was shown to inhibit cell proliferation, migration, invasion, but facilitate apoptosis and autophagy in ...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
AbstractBackgroundAnti-programmed cell death receptor (PD)-1 antibody treatment results in better prognosis than standard chemotherapy in patients with non-small cell lung cancer (NSCLC), especially those with high PD-ligand 1 (PD-L1) expression. However, several studies have reported a lack of antitumor effect of PD-1 antibody, even in patients with high PD-L1 expression. Therefore, reliable predictors of treatment response are urgently needed. The albumin –globulin ratio (AGR) is associated with prognosis in several cancers. We aimed to determine whether AGR is a predictive biomarker of anti-PD-1 antibody response ...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThese results indicate that the SNP538(G  >  A) in theABCC11 gene is a potential determinant for S-1 treatment.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
BRAF gene mutation is found in about 2%-4% of the patients with non-small cell lung cancer (NSCLC). This type of NSCLC is characterized by high malignancy, low efficacy of chemotherapy and poor prognosis. Although the combination treatment of BRAF inhibitor and MEK inhibitor has achieved remarkable results in advanced NSCLC patients with BRAF V600E mutation, which has been written into the National Comprehensive Cancer Network (NCCN) guidelines, severe side effects of the combination therapy are frequently observed. There isn ’t effective treatment strategy after drug resistance, and targeted therapy for non-V600E mu...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Since the development of immune checkpoint inhibitors targeting the programmed cell death 1 –programmed cell death-ligand 1 (PD-1–PD-L1) axis, therapeutic advances have been achieved in non-small cell lung cancer (NSCLC) [1–5]. In advanced NSCLC, combination therapy of immune checkpoint inhibitors and platinum-based chemotherapy has yielded improved overall survival compared with pla tinum-based chemotherapy alone [6–8]. These immune checkpoint inhibitors are believed to prevent PD-1-positive cytotoxic T lymphocytes (CTLs) from lapsing into exhaustion via interplay with PD-L1-positive tumor cells an...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Authors: Ren H, Hu Y, Xie T, Jin C, Hu Y, Yang B Abstract Changes of epidermal growth factor receptor (EGFR) and cytokeratin fragment antigen 21-1 (CYFRA21-1) in patients with advanced non-small cell lung cancer (NSCLC) before and after gefitinib treatment were observed to explore the significance of such changes. A total of 175 patients with advanced NSCLC who were admitted to Hubei Cancer Hospital from July 2012 to October 2015 were collected and divided into two groups: the control group (85 patients who received conventional chemotherapy) and the experimental group (90 patients treated with gefitinib combined w...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Science | Study